Clinical Research Directory
Browse clinical research sites, groups, and studies.
Induction Chemoimmunotherapy to Prevent Laryngectomy in Advanced Laryngeal Cancer and Hypopharyngeal Cancer
Sponsor: Mayo Clinic
Summary
This phase II trial tests the effect of early (induction) standard chemoimmunotherapy with carboplatin, paclitaxel and pembrolizumab in preventing more extensive surgery to remove the voice box (laryngectomy), in patients with laryngeal squamous cell cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or hypopharyngeal cancer of any stage. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of tumor cells. Paclitaxel is in a class of medications called antimicrotubule agents. It stops tumor cells from growing and dividing and may kill them. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Response to treatment with chemoimmunotherapy may help guide further treatment, such as radiation therapy with or without cisplatin. Intensity-modulated radiation therapy (IMRT) is a type of 3-dimensional radiation therapy that uses computer-generated images to show the size and shape of the tumor. Thin beams of radiation of different intensities are aimed at the tumor from many angles. This type of radiation therapy reduces the damage to healthy tissue near the tumor. Intensity-modulated proton therapy is a type of proton beam radiation therapy that uses precise proton beams to target tumors while sparing the surrounding healthy tissue. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of tumor cells. Giving induction chemoimmunotherapy with carboplatin, paclitaxel and pembrolizumab may be an effective strategy to prevent more invasive treatments, such as a laryngectomy, while improving both survival and quality of life in patients with advanced laryngeal squamous cell carcinoma and hypopharyngeal squamous cell carcinoma.
Official title: Induction Bio-Selection Organ Preservation for Advanced Laryngeal Cancer (IBOP)
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
50
Start Date
2026-11-01
Completion Date
2031-02-28
Last Updated
2026-11-09
Healthy Volunteers
No
Conditions
Interventions
Biospecimen Collection
Undergo blood and drain fluid sample collection
Carboplatin
Given IV
Chemotherapy
Given chemotherapy
Cisplatin
Given IV
Computed Tomography
Undergo CT and PET/CT
Electronic Health Record Review
Ancillary studies
Intensity-Modulated Proton Therapy
Undergo intensity-modulated proton therapy
Intensity-Modulated Radiation Therapy
Undergo IMRT
Laryngectomy
Undergo laryngectomy
Paclitaxel
Given IV
Pembrolizumab
Given IV
Positron Emission Tomography
Undergo PET/CT
Questionnaire Administration
Ancillary studies
Radiation Therapy
Undergo adjuvant RT
Locations (1)
Mayo Clinic in Rochester
Rochester, Minnesota, United States